These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16816799)

  • 1. Understanding the results of CATIE in the context of the field.
    Glick ID
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):40-7. PubMed ID: 16816799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic findings from the CATIE trial and their relation to tolerability.
    Nasrallah HA
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):32-9. PubMed ID: 16816798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
    Glazer WM; Conley RR; Citrome L
    CNS Spectr; 2006 Sep; 11(9 Suppl 10):1-13; quiz 14. PubMed ID: 16946697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the CATIE trial on treatment: extrapyramidal symptoms.
    Casey DE
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):25-31. PubMed ID: 16816797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting the efficacy findings in the CATIE study: what clinicians should know.
    Meltzer HY; Bobo WV
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):14-24. PubMed ID: 16816796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome L; Stroup TS
    Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics and metabolics in the post-CATIE era.
    Meyer JM
    Curr Top Behav Neurosci; 2010; 4():23-42. PubMed ID: 21312396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
    Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
    Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.